iShares MSCI Australia ETF vs Revvity Inc — how do they compare? iShares MSCI Australia ETF trades at $28.44 (market cap $1.17B), while Revvity Inc trades at $153.88 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 14.5× iShares MSCI Australia ETF's market cap, and Revvity Inc pays a 0.18% dividend while iShares MSCI Australia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 63 Days and Revvity Inc for 12 Days on average.
| EWA | RVTY | |
|---|---|---|
Market Cap | $1.17B | $16.98B |
Volume | 2,121,231 | 1,456,900 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $157.36 |
52-Week Low | $24.95 | $82.26 |
Typical Hold Time | 63 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
EWA, the iShares MSCI Australia ETF, trades at $28.23, down 1.12% amid broader Australian market weakness. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. Recent institutional activity includes Squarepoint Ops reducing its stake by 91.2% while other firms like Empowered Funds and Cetera Investment Advisers increased positions. The ETF serves as a commodity proxy, benefiting from Australia's export-driven economy.
The outlook remains cautious with technical weakness and mixed institutional sentiment. Upside potential exists if commodity demand drives Australian equities higher, but near-term risks include persistent inflation concerns and tight monetary policy. The Seeking Alpha buy rating targeting $34.83 suggests over 20% upside potential from current levels.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
Latest headlines on both assets
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →